Chinook Therapeutics Inc. (KDNY)
NASDAQ: KDNY
· Real-Time Price · USD
40.39
0.09 (0.22%)
At close: Aug 10, 2023, 10:00 PM
Chinook Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 5.85M | 5.26M | 6.13M | 56.85M | 54.35M | 53.97M | 51.63M | 1.22M | 5M | 4.96M |
Cost of Revenue | 1.73M | 1.72M | 1.29M | 860K | 429K | n/a | n/a | n/a | n/a | n/a |
Gross Profit | 4.12M | 3.54M | 4.84M | 55.99M | 53.93M | 53.97M | 51.63M | 1.22M | 5M | 4.96M |
Operating Income | -251.63M | -215.69M | -185.08M | -112.79M | -86.12M | -92.7M | -99.04M | -145.34M | -129.24M | -93.72M |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 164K | 164K |
Pretax Income | -240.72M | -207.68M | -180.27M | -110.42M | -85.51M | -92.9M | -99.21M | -163.52M | -147.17M | -111.61M |
Net Income | -243.21M | -213.91M | -185.42M | -116.08M | -92.48M | -97.41M | -102.94M | -160.4M | -144.24M | -109.41M |
Selling & General & Admin | 44.18M | 39.83M | 36.29M | 34.27M | 31.09M | 30.22M | 31.9M | 35.18M | 35.94M | 32.05M |
Research & Development | 193.72M | 165.84M | 141.21M | 123.19M | 104.78M | 97.54M | 96.99M | 93.84M | 79.5M | 60.59M |
Other Expenses | 1.3M | 1.73M | 1.2M | 770K | 270K | -198K | -170K | -10K | 71K | 106K |
Operating Expenses | 239.7M | 207.4M | 179.22M | 159.17M | 137.57M | 129.46M | 130.57M | 130.71M | 116.85M | 93.62M |
Interest Expense | 4.82M | 4.82M | 4.82M | n/a | n/a | n/a | n/a | 2K | 2K | 2K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 239.7M | 207.4M | 179.22M | 159.17M | 137.57M | 129.46M | 130.57M | 130.71M | 116.85M | 93.62M |
Income Tax Expense | 2.49M | 6.23M | 4.11M | 3.06M | 4.3M | 1.83M | 2.09M | -3.21M | -2.94M | -2.2M |
Shares Outstanding (Basic) | 71.59M | 70.7M | 69.22M | 67.78M | 61.98M | 58.34M | 51.67M | 44.66M | 43.86M | 42.14M |
Shares Outstanding (Diluted) | 71.59M | 70.7M | 69.22M | 67.78M | 61.98M | 58.34M | 53.69M | 44.66M | 43.86M | 42.14M |
EPS (Basic) | -3.48 | -3.15 | -2.84 | -1.8 | -1.69 | -2.05 | -2.39 | -3.78 | -3.43 | -2.64 |
EPS (Diluted) | -3.48 | -3.15 | -2.84 | -1.81 | -1.7 | -2.06 | -2.4 | -3.78 | -3.43 | -2.64 |
EBITDA | -221.24M | -190.73M | -159.29M | -87.59M | -76.22M | -54.28M | -54.93M | -111.07M | -90.09M | -80.33M |
EBIT | -173.78M | -210.47M | -147M | -94.36M | -36.69M | n/a | n/a | -53.42M | -53.42M | -61.17M |
Depreciation & Amortization | 29.57M | 24.95M | 27.86M | 15.77M | 128K | 4M | 3.93M | 3.93M | 5.72M | 4.62M |